Catalyst Dossier · compiled by Celia 🧫

Regeneron Pharmaceuticals, Inc. (REGN)

Pharmaceutical Preparations · market cap $57.3B · as of 2026-06-23

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-07

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Regeneron Pharmaceuticals (REGN) is a large-cap U.S. biotech with ~$57.5B market cap, anchored by two approved blockbusters — Dupixent (atopic dermatitis and beyond) and Libtayo (cemiplimab, a PD-1 inhibitor advancing through Phase 3 in NSCLC) — alongside a broad pipeline spanning oncology, ophthalmology, and immunology. The company generates substantial revenue (~$14.3B in 2025) and carries net cash of ~$976M, providing durable financial footing. A recent June 2026 PDUFA approval and multiple high-importance readouts (Dupilumab Phase 3, cemiplimab Phase 3, Cemdisiran Phase 3) clustered in H2 2026 through early 2027 make the near-term catalyst calendar unusually dense.

The catalyst path

2026-08-07Earningsimp 5/10
2026-08-19 (est.)Phase 2 · REGN7075imp 7/10
2026-10-07 (est.)Phase 3 · Dupilumabimp 9/10
2026-10-12 (est.)Phase 3 · Ravulizumabimp 9/10
2026-11-02 (est.)Phase 2 · Fixed Dose Combination (FDC) cemiplimab+fianlimabimp 7/10
2026-11-03 (est.)Phase 3 · cemiplimabimp 9/10
2026-12-31 (est.)Data Readoutimp 6/10
2027-01-14 (est.)Phase 2 · Sarilumabimp 7/10

Pipeline

Asset	Phase	Indication
Dupixent	Approved	Atopic Dermatitis
Libtayo	Phase 3	Non-Small Cell Lung Cancer
REGN5458	Phase 2	Multiple Myeloma
Pembrolizumab	Phase 3	Melanoma
Intravitreal Aflibercept Injection (IAI)	Phase 2	Neovascular Age-Related Macular Degeneration
ALN-ANG3	Phase 2	Diabetic Kidney Disease (DKD)
High-dose aflibercept	Phase 2	Neovascular (Wet) Age-Related Macular Degeneration
REGN5678	Phase 2	Metastatic Castration-resistant Prostate Cancer
Alirocumab	Phase 3	Homozygous Familial Hypercholesterolemia
Ezetimibe	Phase 3	Hypercholesterolemia
Cyclophosphamide	Phase 3	Follicular Lymphoma (FL)
Statin	Phase 3	Hypercholesterolemia
REGN5715	Phase 3	Allergic Conjunctivitis
Lenalidomide	Phase 3	Relapsed/Refractory Follicular Lymphoma
Enoxaparin	Phase 2	Venous Thromboembolism
Doxorubicin	Phase 3	Follicular Lymphoma (FL)
REGN5714	Phase 3	Allergic Rhinitis
Pozelimab + Cemdisiran	Phase 3	Generalized Myasthenia Gravis
REGN7075	Phase 2	Advanced Solid Tumors
REGN7041	Phase 2	Active Noninfectious Uveitis Affecting the Posterior Segment

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by Celia. The catalyst path & pipeline above are free.

See Pro

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by Celia. Not financial advice.